MedTrace Logo

One Week Adjuvant Radiotherapy for Breast Cancer

NCT05150535 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2022-05-09

No results posted yet for this study

Summary

* Cancer is the second leading cause of death after cerebrovascular strokes and is a significant obstacle to each nation's future growth.
* Worldwide, Breast cancer is the most common cancer in women and the 5th leading cause of cancer related deaths that comes after lung cancer, colorectal cancer, liver cancer and gastric cancer.
* More than half of all breast cancer cases in the world occur in developing countries. Egypt has a high mortality rate from breast cancer, with a rate of 21.3 per 100,000 cases. Breast cancer is diagnosed at an advanced stage in 60 to 70% of cases in Egypt. The median age at diagnosis in Egypt is 48.5 years, which seems to be a decade younger than in Europe and North America.

Conditions

  • Breast Carcinoma

Interventions

RADIATION

Hypofractionation Radiotherapy.

Patients will receive 40 Gy in 15 fractions to the entire breast and or chest wall over the course of 3 weeks.

RADIATION

Ultra-hypofractionation radiotherapy

Patients will receive 26 Gy in 5 fractions to the entire breast and or chest wall over the course of one week.

Sponsors & Collaborators

  • Sohag University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
85 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-01
Primary Completion
2023-10-01
Completion
2023-10-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05150535 on ClinicalTrials.gov